Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
ACTIV-3/TICO Bamlanivimab Study Group; Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Goodman AL, Chang W, Dewar RL, Gerry NP, Higgs ES, Highbarger H, Murray DD, Murray TA, Natarajan V, Paredes R, Parmar MKB, Phillips AN, Reilly C, Rupert AW, Sharma S, Shaw-Saliba K, Sherman BT, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Davey VJ, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. ACTIV-3/TICO Bamlanivimab Study Group, et al. Among authors: dewar rl. Ann Intern Med. 2022 Feb;175(2):234-243. doi: 10.7326/M21-3507. Epub 2021 Dec 21. Ann Intern Med. 2022. PMID: 34928698 Free PMC article. Clinical Trial.
Passive hemagglutination test for detection of antibodies to human immunodeficiency virus type 1 and comparison of the test with enzyme-linked immunosorbent assay and Western blot (immunoblot) analysis.
Vasudevachari MB, Uffelman KW, Mast TC, Dewar RL, Natarajan V, Lane HC, Salzman NP. Vasudevachari MB, et al. Among authors: dewar rl. J Clin Microbiol. 1989 Jan;27(1):179-81. doi: 10.1128/jcm.27.1.179-181.1989. J Clin Microbiol. 1989. PMID: 2913026 Free PMC article.
The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection.
Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, Dewar RL, Lane HC, Freedman VH, Kaplan G. Klausner JD, et al. Among authors: dewar rl. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):247-57. doi: 10.1097/00042560-199603010-00005. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8603261 Clinical Trial.
Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression.
Kovacs JA, Imamichi H, Vogel S, Metcalf JA, Dewar RL, Baseler M, Stevens R, Adelsberger J, Lambert L, Davey RT Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC. Kovacs JA, et al. Among authors: dewar rl. J Infect Dis. 2000 Oct;182(4):1063-9. doi: 10.1086/315821. Epub 2000 Sep 5. J Infect Dis. 2000. PMID: 10979900 Clinical Trial.
116 results